AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02703662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permacol biologic mesh
Description: Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
Study NCT01297660 — intervention group
Intervention type: OTHER
Intervention: Video-urodynamic examination
Study NCT04764903 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study NCT01116583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
Study NCT01116583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4
Study NCT03681405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Given information about mindful movement and breathing
Study NCT01957085 — intervention group
Intervention type: OTHER
Intervention: observation only
Description: This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
Study NCT00407641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin administration
Description: Patients will receive tinzaparin during the HD session
Study NCT00407641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin administration
Description: Patients will receive Heparin as an anticoagulant during the HD session.
Study NCT03906201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecdysterone
Description: Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
Study NCT03906201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no pharmacologic effect
Study NCT01556789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10
Description: ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
Study NCT05425524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care Bundle
Description: Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
Study NCT01821885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry and a brief advice to quit smoking
Description: During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
Study NCT03681405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01821885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice to quit smoking
Description: During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
Study NCT05148689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride Cream, 1%
Description: Cream
Study NCT05148689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhofade™ (oxymetazoline) cream, 1%
Description: cream
Study NCT05148689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cream
Study NCT04673344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regeneten Collagen Patch
Description: Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
Study NCT01561040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3, Vitamins A, D3 and E
Description: omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
Study NCT01606332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene block with nerve catheter
Description: Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
Study NCT04282460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin practice
Description: Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
Study NCT04282460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular physical exercise
Description: Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
Study NCT04418739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
Study NCT02253992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab
Study NCT02253992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01401985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules
Study NCT03265288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b
Description: LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Study NCT03265288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Study NCT03125980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine plus oxaliplatin before and after surgery
Description: Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)
Study NCT03125980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine plus oxaliplatin after surgery
Description: Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W
Study NCT04013984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accupuncture
Description: In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
Study NCT01025544 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
Study NCT01025544 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix (Haemophilus influenzae type b (Hib) vaccine)
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
Study NCT00699062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: singular
Description: The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
Study NCT00699062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
Study NCT03321630 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Lenvatinib 20 mg orally each day on days 1-7
Study NCT03321630 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
Study NCT03801265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block
Description: Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
Study NCT03801265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum type 3 block
Description: Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
Study NCT03801265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: 0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
Study NCT03801265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
Study NCT00914914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p28
Description: p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
Study NCT00788749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: tablets 25 mg/day
Study NCT00788749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets once daily
Study NCT00788749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone nasal drops
Description: fluticasone nasal drops 800mcg/d
Study NCT00788749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluticasone nasal drops
Description: fluticasone nasal drops 800mcg/d
Study NCT00788749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone nasal spray
Description: fluticasone nasal spray 400 mcg/d
Study NCT00788749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluticasone nasal spray
Description: fluticasone nasal spray 400 mcg/d
Study NCT00062543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion of CD34+ cells
Description: Donor's cells infused directly into liver through a groin catheter (hepatic artery).
Study NCT00062543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobe Spectra
Description: Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
Study NCT02737748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWB-103 Group
Description: Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Study NCT02737748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Study NCT01561508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-amino-butyric acid
Description: gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
Study NCT01561508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylitol
Description: The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
Study NCT04492826 — intervention group
Intervention type: PROCEDURE
Intervention: Postoperative infections rate
Description: Assess the postoperative infection rate after otolaryngology bone flap surgery.
Study NCT00993486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion
Study NCT02125162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Description: Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
Study NCT02337023 — intervention group
Intervention type: RADIATION
Intervention: Brain scintigraphy with injection of Neurolite® (ECD)
Description: Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
Study NCT03681405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03681405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive caring attention phone call
Study NCT00804544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: SPECT/Low-Dose MultiSclice CT
Study NCT01410201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Intravitreal Implant
Description: Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
Study NCT01410201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intravitreal Implant
Description: Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
Study NCT04146324 — intervention group
Intervention type: DRUG
Intervention: nivolumab
Description: Administered as adjuvant therapy as per the market authorization in Australia
Study NCT01756898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ASB17061
Description: Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
Study NCT01756898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo taken once daily for 28 consecutive days.
Study NCT01756898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ASB17061
Description: Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
Study NCT01756898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ASB17061
Description: Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
Study NCT03727347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeca Stylus
Description: Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
Study NCT04238702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 MG 7 days intervention period
Study NCT04238702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50Mg Tab
Description: Losartan 50 MG 7 days intervention period
Study NCT04238702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 7 days intervention period
Study NCT04238702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 7 days intervention period
Study NCT01233531 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: monthly cash transfer payments for attending school
Description: In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
Study NCT01233531 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: B--No cash transfers
Description: No monthly cash transfers
Study NCT02275468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu-zheng-qu-zhuo (FZQZ) oral liquid
Description: FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
Study NCT01737697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (acute phase)
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
Study NCT01737697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (subacute phase)
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
Study NCT01737697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (acute phase)
Description: Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
Study NCT01737697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( subacute phase)
Description: Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
Study NCT00596375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lubricant Instillation
Description: Lubricant jelly instilled in urethra prior to catheterization
Study NCT00596375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Lubricant
Description: 2% Lidocaine lubricant instillation prior to urethral catheterization
Study NCT03249883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SACH prosthetic foot, 1M10 prosthetic foot
Description: In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks.
Study NCT01401985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules
Study NCT01666353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)
Description: PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
Study NCT04281108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Study NCT04281108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet.
Study NCT04281108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.